0
Neurotrope, Inc. Banner Image

Neurotrope, Inc. has reached its limit for free report views

Work for Neurotrope, Inc.? Upgrade Your Profile and unlock all your annual reports.

Neurotrope, Inc.

  • Ticker NTRP
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Neurotrope, Inc. Logo Image
  • 1-10 Employees
  • Based in New York City, New York
NBI is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. NBI has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer’s disease, and preclinical studies for rare diseases and brain injury, including Fragile X syndrome, multiple sclerosis, stroke, Niemann-PickMore Type C disease, Rett syndrome, and traumatic brain injury. The FDA has granted Orphan Drug Designation to NBI for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Neurotrope, Inc.

Most Recent Annual Report

Neurotrope, Inc. MOST RECENT 2019 Form 10K

Report Locked. Neurotrope, Inc. has reached its limit for free report views.